North China Pharmaceutical announced that the company and its subsidiaries Huamin Company and Southern Company participated in the 12th batch of centralized procurement tenders for national pharmaceuticals. Eight drugs, including ciclosporin softgels and tacrolimus capsules, are to be selected for this centralized procurement. The proposed selection results will be announced from July 31, 2026 to August 5, 2026. Among them, sales revenue of ciclosporin softgels in 2025 was 152 million yuan, accounting for 1.65% of the company's revenue for the same period; sales revenue for the first quarter of 2026 was 28.265,800 yuan, accounting for 1.31%. The procurement period starts on the date of execution of the selected results and ends on December 31, 2029.

Zhitongcaijing · 2d ago
North China Pharmaceutical announced that the company and its subsidiaries Huamin Company and Southern Company participated in the 12th batch of centralized procurement tenders for national pharmaceuticals. Eight drugs, including ciclosporin softgels and tacrolimus capsules, are to be selected for this centralized procurement. The proposed selection results will be announced from July 31, 2026 to August 5, 2026. Among them, sales revenue of ciclosporin softgels in 2025 was 152 million yuan, accounting for 1.65% of the company's revenue for the same period; sales revenue for the first quarter of 2026 was 28.265,800 yuan, accounting for 1.31%. The procurement period starts on the date of execution of the selected results and ends on December 31, 2029.